Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

H. Lundbeck A/S announced today that the company has received a Complete Response Letter from the US Food and Drug Administration for Serdolect for the treatment of schizophrenia. The Agency's complete response included request for additional data to best understand the appropriate patient population for which Serdolect could be made available. Lundbeck is currently evaluating the feedback from FDA and will work with the Agency to resolve these outstanding questions and discuss appropriate next steps required to bring Serdolect safely to market.

Today in Regulatory Issues...keeping you current

Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09

GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address